Obsidian Therapeutics, Inc.
13.98USD
+0.0400 (+0.29%)
Not enough data yet
A reading needs 5 members, each at least 14 days old with a track record on this site (simulated portfolios and calls), who shared a take in the last 30 days; 2 of them need a strong record.
Sign in to share your take on OBX.
Revenue
| (USD) | 2026 | 2027 |
|---|---|---|
| FY | 0.0 | 0.0 |
| Q1 | — | — |
| Q2 | — | — |
| Q3 | 0.0 | — |
| Q4 | 0.0 | — |
Revenue
| (USD) | 2026 | 2027 |
|---|---|---|
| FY | -1.82 | -2.79 |
| Q1 | — | — |
| Q2 | — | — |
| Q3 | -.420 | — |
| Q4 | -.507 | — |
Fiscal period: Reported, Estimated. Reported figures: SEC filings (EDGAR). Estimates are sell-side consensus for periods that have not reported. Earnings per share are restated onto today's share basis, so a period before a stock split is comparable with the ones after it.
Revenue to net income
Debt level and coverage